Quick Answer
Ultragenyx Pharmaceutical Inc. reported Cash And Cash Equivalents At Carrying Value of $421.00 million for the year ending 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +142.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Ultragenyx Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $64.80 million | Q2 2013: $13.51 million | Q3 2013: $6.05 million | Q1 2014: $55.45 million | Q2 2014: $17.45 million | Q3 2014: $53.39 million | Q1 2015: $178.04 million | Q2 2015: $52.35 million | Q3 2015: $166.69 million | Q1 2016: $70.76 million | Q2 2016: $55.07 million | Q3 2016: $142.28 million | Q1 2017: $159.50 million | Q2 2017: $90.75 million | Q3 2017: $60.41 million | Q1 2018: $226.73 million | Q2 2018: $110.85 million | Q3 2018: $82.96 million | Q1 2019: $269.71 million | Q2 2019: $131.34 million | Q3 2019: $122.58 million | Q1 2020: $298.19 million | Q2 2020: $335.64 million | Q3 2020: $197.49 million | Q1 2021: $383.79 million | Q2 2021: $290.88 million | Q3 2021: $197.54 million | Q1 2022: $153.99 million | Q2 2022: $159.87 million | Q3 2022: $391.65 million | Q1 2023: $85.77 million | Q2 2023: $102.06 million | Q3 2023: $72.58 million | Q1 2024: $112.25 million | Q2 2024: $480.69 million | Q3 2024: $150.62 million | Q1 2025: $127.06 million | Q2 2025: $176.31 million | Q3 2025: $202.51 million.
- Over the full 15 years of available data (2011 to 2025), Ultragenyx Pharmaceutical Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 3,854.9%.
- Historical annual values: Fiscal year 2025: $421.00 million | Fiscal year 2024: $174.00 million | Fiscal year 2023: $214.00 million | Fiscal year 2022: $132.94 million | Fiscal year 2021: $307.58 million | Fiscal year 2020: $713.53 million | Fiscal year 2019: $433.58 million | Fiscal year 2018: $113.43 million | Fiscal year 2017: $100.49 million | Fiscal year 2016: $161.12 million | Fiscal year 2015: $93.57 million | Fiscal year 2014: $24.32 million | Fiscal year 2013: $7.43 million | Fiscal year 2012: $86.19 million | Fiscal year 2011: $10.65 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: